Alvotech And Fuji Pharma Broaden Biosimilar Alliance In Japan
Number Of New Candidates Added To Partnership
Longtime partners Alvotech and Fuji Pharma – the latter being a minority shareholder in the Icelandic firm – have extended their existing biosimilars partnership in Japan, as Alvotech continues to make strategic moves across the globe.
You may also be interested in...
Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.